

press release

PORCILIS PCV SWINE VACCINE AGAINST PORCINE CIRCOVIRUS TYPE 2 INFECTION LAUNCHED IN EUROPE

BOXMEER (the Netherlands), April 23, 2009 — Intervet/Schering-Plough Animal Health today announces the introduction in Europe of its PORCILIS PCV vaccine against porcine circovirus type 2 (PCV2) infection. The launch of this new subunit vaccine was celebrated this week with a dedicated scientific event near Lisbon (Portugal), attracting hundreds of veterinarians from all over Europe.

The new vaccine has been designed to provide a superior solution for the prevention and management of Porcine Circo Virus-associated Disease (PCVD), a major cause of economic loss in the pig sector. After having gained experience in Germany and Austria on a limited scale, the vaccine will now be introduced in the whole of Europe.

The major advantages of PORCILIS PCV over most existing PCV vaccines are that: (1) it contains the ORF2 subunit as antigen and therefore induces strong immunity against PCV2 infection; (2) it is combined with Xsolve, a proven and potent adjuvant offering long-lasting immunity until the end of the fattening period; and (3) it carries the claim to be able to break through medium-to-high levels of maternally-derived antibodies in piglets. This unique combination of customer advantages will make this new vaccine an attractive new entry in this market.

Infection with PCV2 is known to cause a variety of syndromes in pigs, together known as PCVD. Symptoms may include clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty in breathing, pale skin and jaundice. Field trials with PORCILIS PCV have demonstrated that vaccination of pigs at 3 weeks of age or older not only appears to prevent viremia (presence of virus in the blood and lymphoid tissues), but also reduces weight loss associated with PCV2 infection during the fattening period.

ENDS

more

About the Intervet/Schering-Plough Animal Health PCV vaccines

Intervet/Schering-Plough Animal Health markets two vaccines against PCV2 infection. CIRCUMVENT PCV is produced in the USA and is intended for markets in North-, Central- and South-America, Asia (excl. Japan) and Oceania. CIRCUMVENT PCV was the first PCV2 vaccine receiving a USDA conditional license in 2005 and was launched with a full license in the USA in 2007. PORCILIS PCV is produced in Europe and is intended for the whole of Europe and Japan. Field trials with PORCILIS PCV have been running in Germany and Austria since 2007 and European approval was granted in January 2009.

About Intervet/Schering-Plough Animal Health

Intervet/Schering-Plough Animal Health is focused on the research, development, manufacturing and marketing of animal health products. The company offers customers one of the broadest, most innovative Animal Health portfolios, spanning products to support performance and to prevent, treat and control disease in all major farm and companion animal species. The company is based in Boxmeer, The Netherlands. For more information about Intervet/Schering-Plough Animal Health visit: www.intervet.com

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com